Antibody Drug Conjugate News and Research

RSS

At US hospitals, a drug mix-up is just a few keystrokes away

More than four years ago, Tennessee nurse RaDonda Vaught typed two letters into a hospital's computerized medication cabinet, selected the wrong drug from the search results, and gave a patient a fatal dose.

29 Apr 2022

Study demonstrates multinuclear MRI is sensitive to functional pulmonary changes in the follow up of patients hospitalized with COVID-19

In this study, researchers subjected patients to a pulmonary 1H and 129Xe MRI protocol at 6, 12, 25, and 50 weeks after hospitalization.

11 Apr 2022

NK cells complexed with bispecific antibody elicit high response rate in patients with resistant lymphomas

Natural killer (NK) cells derived from cord blood that were activated and complexed with a CD30/CD16A bispecific antibody elicited an 89 percent overall response rate in patients with relapsed or refractory CD30+ lymphoma, according to results from a phase I/II clinical trial presented at the AACR Annual Meeting 2022, held April 8-13.

10 Apr 2022

Promising data from early clinical trials of new anticancer therapies presented at ESMO Congress 2021

Data from early clinical trials presented at the ESMO Congress 2021 suggest that new anticancer treatments are on the horizon, with a clear emphasis on precision medicine.

24 Sep 2021

$1.3 million in NIH funding to enable drug delivery technology research

Two National Institute of Health grants totaling over $1.3 million will enable research into antibody-mediated drug delivery technology for the treatment of cancer and autoimmune disorders. L. Nathan Tumey, assistant professor of pharmaceutical sciences at Binghamton University, State University of New York, is the Principal Investigator on both grants -; $1.2 million from the National Institute of General Medical Sciences and $150,000 from the National Institute of Allergy and Infectious Diseases.

31 Aug 2021

MGH researchers discover how triple-negative breast cancer can evade powerful drugs

Massachusetts General Hospital researchers have identified for the first time how a highly aggressive form of breast cancer can evade one of the most powerful and effective drugs used to treat it, reporting their findings in Cancer Discovery, a journal of the American Association for Cancer Research.

17 Aug 2021

MUSC Hollings Cancer Center part of promising phase 2 lymphoma clinical trial

MUSC Hollings Cancer Center was one of 28 clinical sites around the world that participated in the LOTIS-2 trial to test the efficacy of Loncastuximab tesirine, a promising new treatment for aggressive B-cell lymphoma.

23 Jul 2021

New antibody-drug conjugates also kill non-targeted neighboring tumor cells

How do you kill tumor cells that can't be targeted? Get their more susceptible neighbors to help.

22 Jun 2021

LegoChem Biosciences and Iksuda Therapeutics expand License Agreement for development of antibody-drug conjugates

Iksuda Therapeutics today announced that it has expanded its research collaboration and License Agreement with LegoChem Biosciences, Inc.

From Iksuda Therapeutics 22 Jun 2021

Iksuda Therapeutics closes $47 million financing round

Iksuda Therapeutics (Iksuda) has announced it has completed a US $47 million (circa GB £34 million) financing round, co-led by Mirae Asset Capital and its subsidiaries, Celltrion and Premier Partners, with the Company being advised by Ashfords LLP. The funding will support the advancement of Iksuda’s lead ADC assets and expansion of its payload and conjugation platform technologies.

From Iksuda Therapeutics 8 Jun 2021

Study provides new insight on how HER2-low tumors may evolve in breast cancer patients

The finding that breast tumors can evolve to express low HER2 potentially widens the number of patients who can benefit from new investigational agents, typically novel antibody-drug conjugate therapies, that are currently in clinical trials for HER2-low tumors.

8 May 2021

UMass Amherst researchers achieve breakthrough in the fight against cancer

A team of researchers at the Center for Bioactive Delivery at the University of Massachusetts Amherst's Institute for Applied Life Sciences has engineered a nanoparticle that has the potential to revolutionize disease treatment, including for cancer.

6 May 2021

Researchers develop an effective strategy to fight against chronic myelomonocytic leukemia

Leukemias are debilitating cancers of the hematopoietic or blood-forming cells of the bone marrow. Now, researchers at Tokyo Medical and Dental University describe an ingenious strategy against chronic myelomonocytic leukemia (CMML) wherein an antibody-drug conjugate (ADC) comprising a cytotoxic drug payload linked to an antibody that selectively targets specific cell lines effectively blocks malignant cell proliferation at source.

16 Apr 2021

New technology shows encouraging results for treating osteosarcoma

A preclinical study led by researchers at The University of Texas MD Anderson Cancer Center shows an antibody-drug conjugate (ADC) targeting surface protein MT1-MMP can act as a guided missile in eradicating osteosarcoma tumor cells without damaging normal tissues.

13 Apr 2021

Targeted therapy achieves excellent outcomes, reduces side effects in high-risk Hodgkin lymphoma

Scientists are reporting results of the first frontline clinical trial to use targeted therapy to treat high-risk pediatric Hodgkin lymphoma.

8 Apr 2021

Advancing the Diagnosis and Treatment of Ovarian Cancer

In this interview, News-Medical talks to Dr. Marcos Quintela Vasquez about the work he is conducting regarding the diagnosis and treatment of ovarian cancer in partnership with Porvair Sciences.

From Porvair Sciences Limited 7 Apr 2021

Researchers confirm a threshold value for non-invasive imaging biomarker

Breast cancer is the commonest fatal cancer in women. Early detection increases a woman's chances of recovery. Magnetic Resonance Imaging (MRI) is an accurate technique for detecting and classifying tumors in breast tissue.

2 Mar 2021

Study: Targeted therapy prolongs survival in patients with advanced bladder cancer

In a new study led by researchers at Yale Cancer Center, the drug enfortumab vedotin (EV) significantly prolonged survival as compared with standard chemotherapy in patients with locally advanced or metastatic urothelial carcinoma or bladder cancer, who had previously received platinum-based treatment and a PD-1–PD-L1 inhibitor.

15 Feb 2021

Pediatric brain tumors can be classified using diffusion weighted imaging and machine learning

Diffusion weighted imaging and machine learning can successfully classify the diagnosis and characteristics of common types of pediatric brain tumors a UK-based multi-center study, including WMG at the University of Warwick has found.